Abstract
We read the recent article by Albain and colleagues1 with interest. In this translational study, the 21-gene recurrence assay (Genomic Health, Redwood City, CA, USA) was successfully performed on 601 samples from Southwest Oncology Group-8814, INT-0100. We were surprised that results were not reported for the 234 tissue samples from patients who received cyclophosphamide, doxorubicin, and fluorouracil with concurrent tamoxifen (CAFT). This subset was excluded after the results were obtained despite comprising more than a third of the successful 21-gene assays in the study.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
